COMPANY PROFILE
M2BIO SCIENCES INC.
SYMBOL : WUHN
SECTOR : PSYCH.
O/S : 48 M
MARKET CAP : $ 15 M
MARKET OPPORTUNITY : UP TO $350 B
M2BIO SCIENCES INC. is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals.
Psilocybin Study with University Of Pretoria, South Africa
M2BIO SCIENCES INC. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies
MAJOR DEVELOPMENT
M2BIO SCIENCES INC. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial in Psilocybin research for medical conditions such as alcohol addiction and related mental health diseases & cardiovascular conditions.
COMPANY BRIEF
| Researching and developing indications for psilocybin new therapies
| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands
| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions
HIGHLIGHTS
| First in market to research psilocybin for treatment of alcoholism and cardiovascular tissue
| Established distribution channels in the US, Canada, Europe and Africa
| Early stage entry into cannabinoid and psilocybin company- Enormous upside
| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases
M2BIO DEVELOPMENT
M2Bio ACQUISITIONS, DIVISIONS & STRATEGIC PARTNERS
WUHAN Cosmetics and food name Dr. AnnaRx
WUHAN infused beverages MEDSPRESSO CBD
WUHAN infused beverages MEDSPRESSO Mushroom
VERY SMALL FLOAT
M2BIO SCIENCES INC. O/S is ONLY 48 millions with a small float of 10 millions
M2Bio COMPARABLE
RVV | OTC
COMPANY INFORMATION
JOIN FACEBOOK INVESTOR GROUP
Wuhan last news | article
M2Bio Sciences (Wuhan General Group) Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility
CAPE TOWN, SA / ACCESSWIRE / April 20, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…
Medspresso(TM) Partners with CNC Products for Online Listing and CSR Activities
CAPE TOWN, SA / ACCESSWIRE / April 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
Wuhan (M2bio Sciences) Launches Medspresso CBD Infused Whole Bean Roasted Coffee
CAPE TOWN, SA / ACCESSWIRE / March 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
Wuhan (M2Bio Sciences, Inc) Announces Opening Cape Town Office
CAPE TOWN, SA / ACCESSWIRE / March 22, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
Medspresso Partners up with Zootly: South Africa’s Leading Cannabis Destination
CAPE TOWN, SA / ACCESSWIRE / February 9, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…
A penny stock in the psychedelic market one step ahead ?
It wasn’t until early 2020 that investors started hearing about the psychedelic market. This investor enthusiasm is certainly not unrelated to the report from the Cannacord firm which estimates the…
Financier Sheldon Inwentash Joins M2Bio Sciences (Wuhan General Group) as Strategic Advisor
OTC PINK : WUHN CAPE TOWN, SA / ACCESSWIRE / January 27, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based…
Video: Interview with the CEO of M2Bio Sciences and ThreeD Capital Inc.
OTC PINK : WUHN On December 30, 2020, M2Bio Sciences announced a private placement of $ 450,000.00 USD from ThreeD Capital Inc. In these interviews with Jeff Robinson, CEO of…
Psychedelic market: What’s coming for M2Bio Sciences in 2021 ?
OTC PINK : WUHN The CEO of M2Bio Sciences (Wuhan General Group), Jeff Robinson, provided an update on the company in an interview which has just been published. In this…
M2Bio Sciences closes Acquisition of Tsime Pharmaceuticals (PTY) Limited
CAPE TOWN, SA / ACCESSWIRE / January 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
M2bio Sciences (Wuhan General Group) Announces $450,000 USD Private Placement by ThreeD Capital Inc.
CAPE TOWN, SA / ACCESSWIRE / December 30, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
M2Bio Sciences, Inc (Wuhan General Group) Launches Hemp Product Research & Development Division
CAPE TOWN, SA / ACCESSWIRE / December 23, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…